Clinical trials: Psychological Disorders
Alzheimer's Disease
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or study ELN115727-302.
- Trial name
- NCT00937352
- Testing
- Bapineuzumab
- Where
- 191 sites in United States, Austria and 1 more
- Volunteers
- 896 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Bipolar Disorders, Manic Disorder
A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder
The purpose of the study is to evaluate the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo as add-on therapy to mood stabilizers in the treatment of manic episodes associated with bipolar…
- Trial name
- NCT00253149
- Testing
- risperidone
- Volunteers
- 158 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimer Disease
Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill
This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients with Alzheimer's disease over a 210-day period.
- Trial name
- NCT06597058
- Testing
- MAR
- Where
- 16 sites in United States
- Volunteers
- 121 people
- Sponsor
- Noah Pharmaceuticals, Inc.
Major Depressive Disorder
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18 mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder…
- Trial name
- NCT01185340
- Testing
- LY2216684, SSRI
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 1,056 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Schizophrenia, Schizoaffective Disorder
As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations
The purpose of this study is to compare the steady-state pharmacokinetics of paliperidone after oral administration of 15 mg extended-release (ER) OROS paliperidone once daily with the steady-state pharmacokinetics of…
- Trial name
- NCT00796185
- Testing
- Paliperidone ER
- Volunteers
- 62 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
This is a study in chronic stable Schizophrenia with the purpose to answer the question of whether agonism of the nicotinic alpha7 receptor is capable of enhancing cognition in a well defined chronic stable patient population…
- Trial name
- NCT01730768
- Testing
- AQW051
- Where
- 13 sites in United States
- Volunteers
- 147 people
- Sponsor
- Novartis Pharmaceuticals
Bipolar Disorder, Depression
A Study Of Kappa Opioid Receptor Occupancy Of PF-04455242, Using PET (Positron Emission Tomography)
This is a subject blind, investigator and sponsor open, randomized study consisting of 2 parts. Up to 15 healthy subjects will be included in the study.
- Trial name
- NCT00939887
- Testing
- PF-04455242
- Where
- 3 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Alzheimer Disease
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.
- Trial name
- Reτain (NCT06544616)
- Testing
- JNJ-64042056
- Where
- 90 sites in United States, Australia and 7 more
- Volunteers
- 55 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Depressive Disorder, Major
A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
A Placebo Controlled Study Evaluating Efficacy And Safety of Medication In Patients With Major Depressive Disorder (MDD)
- Trial name
- NCT00048204
- Testing
- GW597599B, paroxetine
- Volunteers
- 372 people
- Sponsor
- GlaxoSmithKline
Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo…
- Trial name
- HOPE4MCI (NCT03486938)
- Testing
- AGB101 220 mg tablet
- Where
- 24 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- AgeneBio
Schizophrenia
To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Schizophrenia is a brain disease. The condition may be associated with acute psychotic episodes and long-term disability despite remission from the acute symptoms.
- Trial name
- NCT00150176
- Testing
- Asenapine - Open Label, Asenapine - Double Blind
- Volunteers
- 831 people
- Sponsor
- Organon and Co
Bipolar Disorder, Bipolar Depression
Seroquel in Bipolar Depression Versus SSRI
The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.
- Conditions
- Bipolar Disorder, Bipolar Depression, Depression
- Trial name
- EMBOLDEN II (NCT00119652)
- Testing
- quetiapine fumarate (Seroquel), paroxetine, mood stabilizing activity
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 676 people
- Sponsor
- AstraZeneca
Alzheimer's Disease, Mild Cognitive Impairment
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
This study will evaluate the safety, tolerability, and pharmacokinetics of MK-4334 administered once daily (QD) in participants with Alzheimer's clinical syndrome receiving a stable, daily dose of donepezil 10 mg, taken orally…
- Trial name
- NCT03740178
- Testing
- MK-4334, Donepepzil
- Sponsor
- Merck Sharp & Dohme LLC
Acute Pain, Anxiety
Effect of Virtual Reality Technology for Managment of Acute Pain in Outpatient Hysteroscopy
Performing out patient diagnostic and operative gynecological procedures is becoming more popular having the benefits of reducing risks of general anaesthetia, decreasing healthcare burden and increasing satisfaction for both…
- Trial name
- NCT06424093
- Testing
- Virtual Reality Technology
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Egymedicalpedia
HIV Infections
Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia
The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia. Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle…
- Trial name
- NCT00002414
- Testing
- CPI-1189
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Centaur Pharmaceuticals
Attention Deficit Hyperactivity Disorder
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults.
- Trial name
- NCT00510276
- Testing
- Atomoxetine hydrochloride
- Where
- 29 sites in United States, Puerto Rico
- Volunteers
- 445 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
The precursor study (SCA101469) was an open-label, prospective multicentre study in adult subjects diagnosed with bipolar disorder consisting of 36 weeks treatment with lamotrigine.
- Trial name
- NCT00360126
- Testing
- lamotrigine
- Where
- 3 sites in Australia
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease
Open-Label Extension Protocol to SNK01-AD01 Study
Open-Label Extension Protocol to SNK01-AD01 Study
- Trial name
- NCT07228078
- Testing
- SNK01
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NKGen Biotech, Inc.
Nicotine Addiction, Cigarette Smoking
Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use
Three hundred-twenty (320) adult smokers of menthol or non-menthol combustible cigarettes will be recruited and randomly assigned to one of five groups (n=64/group), who will be asked to switch for 12 weeks to ad libitum use of…
- Trial name
- DUAL (NCT02870218)
- Testing
- Smoking research cigarettes with e-cigarette, Nicotine discrimination thresholds
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.